1.1 Kubva pakugadzirisa membrane kuenda kuCerebrovascular regulation

Sezvo Citicoline yakatanga kugadzirwa neTakeda Pharmaceutical yekuJapan muna 1956, nhoroondo yekushandiswa kwayo inogona kutorwa senhoroondo yekuvandudza kwekuziva:

• 1980s:Inongoshandiswa sesero membrane kugadzirisa agent mushure mekurova

• 2010s:Yakawanikwa kuti inogona kuwedzera cerebral blood perfusion (PET-CT yakaratidza kuwedzera kwe23% mu temporal lobe blood flow)

• Muna 2024,iyo NIH yeUnited States yakanyora sechinhu chakakosha chekutonga che "neurovascular coupling"

1.2 Kuwedzera kukura kwemusika wepasi rose

Zvinoenderana nedata reEvaluate Pharma:

Kutengeswa kwepasirese kwakasvika mabhiriyoni 4.7 emadhora ekuAmerica muna 2024 (CAGR 12.3%).

Iko kushandiswa kwezvinodhaka muzvipatara zvemuenzaniso muChina kwakawedzera ne400% mumakore matatu

Zviratidzo zvakawedzerwa ku:

Vascular dementia (MMSE mamakisi akavandudzwa ne2.1 mapoinzi)

Kukuvara kwehuropi (GOS prognostic scale yakawedzera ne1.5 mamakisi)

Chitsauko Chechipiri: Black-bhokisi Kutsemuka kweMechanism Yekuita

?

2.1 Nzira nhatu dzekuita

Target effect uchapupu nhanho: Phosphatidylcholine synthesis inogadzirisa neuronal membrane kutendeseka Kirasi I: Acetylcholine precursors inowedzera neurotransmitter kutapurirana Kirasi IIA: Nitric oxide synthase regulation inovandudza microvascular dilation (dhayamita kuwedzera ne18%) Kirasi IIB.

?

2.2 Clinical yegoridhe hwindo nguva

Ongororo ye2024 neFirst Affiliated Hospital yeSun Yat-sen University inoratidza:

Intravenous injection ye1000mg mukati maawa matanhatu mushure mecerebral infarction inogona kuchengetedza nzvimbo ye ischemic penumbra kusvika ku7.2cm.3

Nekudaro, pakanga pasina musiyano wakakosha wenhamba apo hutongi hwakapfuura maawa makumi manomwe nemaviri (p = 0.34).

Chitsauko chechitatu: The Vortex of Controversy

?

3.1 Kusava nechokwadi pamusoro peKushanda

UK NICE Guidelines: Zvinofungidzirwa kuti humbowo huripo hahuna kukwana kutsigira hutano inishuwarenzi yekuvhara (mutengo-kushanda-reshiyo ￡45,000/QALY)

Lancet Neurology **2025 Meta-analysis: Hapana mutsauko wakakosha kubva ku placebo muboka rakapfava cognitive impairment (p=0.21)

3.2 Chaos in Commercial Promotion

The National Medical Products Administration's 2024 chiziviso:

Mabhizinesi gumi nemaviri akawedzera zviratidzo (kukurudzira "adjuvant therapy" se "kudzoreredza dementia").

Miedzo pane imwe e-commerce papuratifomu inoratidza kuti izvo chaizvo zvirimo zve32% zvekugadzirira nemuromo zviri pasi pe70% yehuwandu hwakanyorwa.

Chitsauko Chechina: Frontiers of Technological Breakthroughs

?

4.1 Sistimu Itsva yekutumira Mishonga

Ropa-uropi chinovharira chinopinda peptide yakagadziridzwa liposomes (Patent yePeking University Team, CN202410123456.7)

Inoteerera yakasimudzwa-yakaburitswa microneedles (Mhuka kuyedza paSeoul National University muSouth Korea inoratidza kuwedzera katatu kwebioavailability)

?

4.2 Kwayedza yeMushonga Wega

Tsvakiridzo yakabatana yeBgi yakawana kuti:

Mhedzisiro yemishonga yeCDP-cholinesterase gene polymorphic population (inoverengera 31% yevagari vekuAsia) yakawedzera ne47%

Chitsauko cheshanu Real-world Data yeVarwere

?

5.1 Vanobatsirwa Nyaya

Chirekodhi kubva kuchipatara chepamusoro muHangzhou: Mushure mekurapwa kwakabatanidzwa, iyo cerebral yekuyerera kweropa inochengeterwa huwandu hwemurwere ane makore makumi matanhatu nemaviri ane cerebral infarction akapora kubva pa32% kusvika 89%.

5.2 Kuzvitaura wega kwebato risingaite

"Kuitora kwehafu yegore nguva dzose, mari yepamwedzi ye300 yuan yakangounza kusagadzikana kwemudumbu" - nhoroondo yebvunzurudzo yaMs. Li, murwere anobva kuBeijing.